Arete Wealth Advisors LLC acquired a new stake in shares of Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,392 shares of the company’s stock, valued at approximately $142,298,000,000. Arete Wealth Advisors LLC owned about 0.07% of Unity Biotechnology at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Prime Capital Investment Advisors LLC purchased a new stake in shares of Unity Biotechnology during the fourth quarter valued at $31,000. Virtu Financial LLC boosted its position in shares of Unity Biotechnology by 25.4% during the second quarter. Virtu Financial LLC now owns 62,640 shares of the company’s stock valued at $35,000 after buying an additional 12,681 shares during the last quarter. Jane Street Group LLC purchased a new position in Unity Biotechnology in the fourth quarter worth about $37,000. Schonfeld Strategic Advisors LLC purchased a new position in Unity Biotechnology in the fourth quarter worth about $38,000. Finally, State Street Corp boosted its position in Unity Biotechnology by 32.4% in the third quarter. State Street Corp now owns 172,640 shares of the company’s stock worth $68,000 after purchasing an additional 42,200 shares during the last quarter. 24.19% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on UBX. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Unity Biotechnology in a research report on Tuesday, March 28th. Citigroup raised their price objective on Unity Biotechnology from $5.00 to $6.00 in a research note on Friday, May 26th. Mizuho decreased their price objective on Unity Biotechnology from $12.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, March 28th. Finally, Wedbush downgraded Unity Biotechnology from an “outperform” rating to a “neutral” rating in a research note on Monday, June 26th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.75.
Unity Biotechnology Stock Performance
Unity Biotechnology (NASDAQ:UBX – Get Free Report) last issued its earnings results on Tuesday, May 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.34. Equities research analysts expect that Unity Biotechnology, Inc. will post -3.46 EPS for the current fiscal year.
About Unity Biotechnology
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
Featured Articles
- Five stocks we like better than Unity Biotechnology
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 Housing Stocks to Avoid as Interest Rates Rise
- Insider Trades May Not Tell You What You Think
- AMC: Is a Big Squeeze in the Coming Attractions?
- How to Invest in Cybersecurity
- Rivian: A Roaring Rise Or Time To Cash Out?
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
